Affected Systems |
|
|
|
|
|
|
|
|
|
|
cardiovascular system
|
|
|
|
|
|
|
|
|
√
|
absent vitelline blood vessels
|
|
|
|
|
|
|
|
|
√
|
cellular
|
|
|
|
|
|
|
√
|
|
|
abnormal megakaryocyte differentiation
|
|
|
|
|
|
|
√
|
|
|
embryo
|
|
|
|
|
|
|
|
|
√
|
absent vitelline blood vessels
|
|
|
|
|
|
|
|
|
√
|
decreased embryo size
|
|
|
|
|
|
|
|
|
√
|
pale yolk sac
|
|
|
|
|
|
|
|
|
√
|
abnormal embryonic erythropoiesis
|
|
|
|
|
|
|
|
|
√
|
growth/size/body
|
√
|
|
|
|
|
|
√
|
|
√
|
decreased embryo size
|
|
|
|
|
|
|
|
|
√
|
decreased fetal size
|
|
|
|
|
|
|
√
|
|
|
enlarged spleen
|
√
|
|
|
|
|
|
|
|
|
hematopoietic system
|
√
|
√
|
√
|
√
|
N
|
N
|
√
|
|
√
|
hematopoietic system phenotype
|
|
|
|
|
N
|
N
|
|
|
|
abnormal embryonic erythropoiesis
|
|
|
|
|
|
|
|
|
√
|
enlarged spleen
|
√
|
|
|
|
|
|
|
|
|
abnormal definitive hematopoiesis
|
|
|
√
|
√
|
|
|
|
|
|
extramedullary hematopoiesis
|
√
|
|
|
|
|
|
|
|
|
anemia
|
√
|
√
|
√
|
√
|
|
|
|
|
√
|
abnormal bone marrow cell morphology/development
|
|
|
|
|
|
|
√
|
|
|
abnormal megakaryocyte morphology
|
√
|
|
√
|
√
|
|
|
√
|
|
|
abnormal megakaryocyte differentiation
|
|
|
|
|
|
|
√
|
|
|
increased megakaryocyte cell number
|
|
|
√
|
√
|
|
|
√
|
|
|
decreased erythroid progenitor cell number
|
|
|
√
|
√
|
|
|
|
|
√
|
abnormal megakaryocyte progenitor cell morphology
|
|
|
√
|
√
|
|
|
|
|
|
abnormal proerythroblast morphology
|
√
|
|
|
|
|
|
|
|
|
abnormal erythrocyte morphology
|
|
|
√
|
√
|
|
|
√
|
|
|
abnormal erythropoiesis
|
√
|
√
|
√
|
√
|
|
|
|
|
|
abnormal stress erythropoiesis
|
|
|
|
|
|
|
√
|
|
|
decreased erythrocyte cell number
|
|
|
√
|
√
|
|
|
|
|
|
decreased hematocrit
|
√
|
|
√
|
√
|
|
|
|
|
|
decreased hemoglobin content
|
|
|
√
|
√
|
|
|
|
|
|
anisocytosis
|
|
|
|
|
|
|
√
|
|
|
abnormal platelet morphology
|
|
|
√
|
√
|
|
|
√
|
|
|
abnormal thrombopoiesis
|
|
|
|
|
|
|
√
|
|
|
thrombocytopenia
|
√
|
|
|
|
|
|
√
|
|
|
thrombocytosis
|
|
|
√
|
√
|
|
|
|
|
|
increased leukocyte cell number
|
|
|
√
|
√
|
|
|
|
|
|
abnormal mononuclear cell morphology
|
|
|
|
|
|
|
√
|
|
|
decreased spleen red pulp amount
|
√
|
|
|
|
|
|
|
|
|
decreased spleen white pulp amount
|
√
|
|
|
|
|
|
|
|
|
pale spleen
|
√
|
|
|
|
|
|
|
|
|
homeostasis/metabolism
|
|
|
|
|
|
|
|
√
|
|
abnormal iron level
|
|
|
|
|
|
|
|
√
|
|
immune system
|
√
|
|
√
|
√
|
|
|
√
|
|
|
enlarged spleen
|
√
|
|
|
|
|
|
|
|
|
abnormal thrombopoiesis
|
|
|
|
|
|
|
√
|
|
|
increased leukocyte cell number
|
|
|
√
|
√
|
|
|
|
|
|
abnormal mononuclear cell morphology
|
|
|
|
|
|
|
√
|
|
|
decreased spleen red pulp amount
|
√
|
|
|
|
|
|
|
|
|
decreased spleen white pulp amount
|
√
|
|
|
|
|
|
|
|
|
pale spleen
|
√
|
|
|
|
|
|
|
|
|
integument
|
|
|
|
|
|
|
√
|
|
|
pallor
|
|
|
|
|
|
|
√
|
|
|
liver/biliary system
|
|
|
|
|
|
|
|
|
√
|
pale liver
|
|
|
|
|
|
|
|
|
√
|
mortality/aging
|
√
|
|
|
|
|
|
|
|
√
|
decreased survivor rate
|
√
|
|
|
|
|
|
|
|
|
premature death
|
√
|
|
|
|
|
|
|
|
|
embryonic lethality during organogenesis, complete penetrance
|
|
|
|
|
|
|
|
|
√
|